Literature DB >> 7223314

Iliac crest bone mass and remodelling in acromegaly.

J Halse, F Melsen, L Mosekilde.   

Abstract

Iliac crest bone biopsies from 18 patients with active acromegaly, of whom 11 had received tetracycline double-labelling, were evaluated by quantitative histomorphometry and compared with age- and sex-matched normal controls. A significant increase (P less than 0.01) was found in both cortical (175%) and trabecular (130%) bone mass. In trabecular bone, resorption surfaces and active (tetracycline-labelled) and total formation surfaces were increased (P less than 0.05 and P less than 0.01, respectively) causing an enhanced bone turn-over at tissue level (P less than 0.01). The increased trabecular bone mass indicates a positive net balance per remodelling cycle and, therefore, larger than normal bone remodelling units, which in part may explain the increased bone turn-over at tissue level. The activity of the osteoblasts active in mineralization (the appositional rate) was increased (P less than 0.01) and positively related to the fasting serum growth hormone levels (Rs = 0.69, P less than 0.05). The average activity of active and inactive osteoblasts (bone formation rate at basic metabolic unit (BMU) level) was insignificantly increased. The proportion of active (tetracycline labelled) to nonactive formation surfaces was normal. The bone changes were unrelated to serum levels and urinary excretions of calcium and phosphorus or to renal excretion of total and non-dialyzable hydroxyproline or cAMP.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7223314     DOI: 10.1530/acta.0.0970018

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  13 in total

Review 1.  Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?

Authors:  I Chiodini; V Trischitta; V Carnevale; A Liuzzi; A Scillitani
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

Review 2.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Bone histomorphometry in acromegaly patients with fragility vertebral fractures.

Authors:  L Dalle Carbonare; V Micheletti; E Cosaro; M T Valenti; M Mottes; G Francia; M V Davì
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

4.  Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.

Authors:  M Terzolo; A Piovesan; G Osella; A Pia; G Reimondo; C Pozzi; C Raucci; M Torta; P Paccotti; A Angeli
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

5.  Osteoporosis in longstanding acromegaly: characteristic changes of vertebral trabecular architecture and bone matrix composition.

Authors:  J Diebold; B Bätge; H Stein; G Müller-Esch; P K Müller; U Löhrs
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

6.  Serum bone Gla protein as a marker of bone turnover in acromegaly.

Authors:  M Marazuela; B Astigarraga; M J Tabuenca; J Estrada; F Marín; T Lucas
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

7.  Bone mineral density and circulating cytokines in patients with acromegaly.

Authors:  S Longobardi; C Di Somma; F Di Rella; N Angelillo; D Ferone; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

Review 8.  Renal effects of growth hormone. II. Electrolyte homeostasis and body composition.

Authors:  G D Ogle; A R Rosenberg; G Kainer
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

10.  Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly.

Authors:  C de la Piedra; J Larrañaga; N Castro; C Horcajada; A Rapado; J L Herrera Pombo; E Carbó
Journal:  Calcif Tissue Int       Date:  1988-07       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.